Cerus Corp(CERS) Finding the best opportunities to buy and sell stocks daily.

Sector:

Healthcare

Description:

Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma that is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; and INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company has a collaboration with the National Trauma Institute to supply Intercept plasma for use in the plasma resuscitation without lung injury (PROpOLIs) clinical study. Cerus Corporation was founded in 1991 and is headquartered in Concord, California.

Current Price

$5.82

RSI

54.304

Beta:

1.334

December 31, 2020
57.6M
64.6M
-18.2M

19.987 %
5.413 %
-5.790 %
6.618 %

$114,249,000
$93,774,000
$76,051,000
$51,326,000
$39,275,000
$34,223,000
21.834 %
23.304 %
48.172 %
30.684 %
14.762 %

$-59,573,000
$-70,981,000
$-57,335,000
$-56,698,000
$-62,731,000
$-59,539,000
16.072 %
-23.800 %
-1.123 %
9.617 %
-5.361 %

News

Press Releases

Notable Dates

All stock recommendations and comments are all opinions. Investors should be cautious about any and all stock recommendations and should consider the source of any advice on stock selection. Various factors, including personal ownership, may influence or factor into a stock analysis or opinion. All investors are advised to conduct their own independent research into individual stocks before making a purchase decision. In addition, investors are advised that past stock performance is not indicative of future price action.